A practical reference on human growth hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-10. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Production == One method for industrial production of dried cherries involves first dipping them in a boiling 0.5–2% solution of sodium carbonate (NaCO3) for up to 20 seconds, and then rinsing in cool water; this induces small cracks in the skin and speeds up the drying process. Some other possible materials for the dipping solution include ethyl oleate and oleyl alcohol; adding alkalis like potassium carbonate (K2CO3) to such a dip was shown to have no positive effect on drying time. Such results had already been demonstrated in scientific research by the 1940s. Dried cherries might also be produced by freeze drying or air drying. After drying, they typically have a moisture content of around 25%. Adding sulfur dioxide (SO2) may help to improve color and flavour retention over long periods of storage. Sweet varieties recommended for drying include Lambert, Royal Ann, Napoleon, Van, or Bing; tart varieties recommended for drying include Early Richmond or Large Montmorency. Most cherries sold in North America are sour varieties (either Montmorency or Morello). The first recorded experiments attempting to dry Montmorency tart cherries were performed in the late 1970s by professors at Utah State University. After drying the cherries, they were rolled in sugar and then sampled as "snow cherries".
The same number of families will be uprooted, business inconvenienced or lost, and farms destroyed . . .mudflats [from reservoir drawdowns] would still blight the land that now provides a classic definition of nature's beauty." He proposed legislation authorizing the Army Corps of Engineers to discover the "recreational, conservation, and preservation uses" of the river in 1972 and 1973. Then, in 1974, he introduced a House Bill that would designate the river part of the National Wild and Scenic Rivers System (NWSRS). North Carolina Senators Sam Ervin and Jesse Helms introduced a parallel bill that passed the Senate, but the House Bill stalled. It was not until 1976 that Congress would amend the Wild and Scenic Rivers Act, adding 26.5 miles of the river to the NWSRS and effectively thwarting the Blue Ridge Power Project. Also in 1974, Mizell proposed an amendment to the Legal Services Corporation Act, preventing the proposed government agency from handling desegregation suits. The amendment was included in the final version of the bill which passed. He was an opponent of desegregation busing as well, stating "Quality education...cannot be achieved while overwhelming additional expenses and administrative duties are required to implement court-ordered busing." The Watergate scandal affected Republican House members in 1974, and Mizell was upset by Democrat Stephen L. Neal, 64,634 (52.4 percent) to 59,182 (47.6 percent). Mizell had been considering running for the Senate to replace Ervin, but he opted to run for the House again, considering this a safer election bet.
Reflecting on past positive experiences can influence current mood, and assist in building positive expectations for the future. There is research that suggests a person's focus influences level of happiness, where thinking too much about happiness can be counter-productive. Rather than asking: "Am I happy?" – which when posed just 4 times a day, starts to decrease happiness, it might well be better to reflect on one's values (e.g., "Can I muster any hope?"). Asking different questions can assist in redirecting personal thoughts, and perhaps, lead to taking steps to better apply one's energies. The personal answer to any particular question can lead to positive actions, and hopefulness, which is a very powerful, and positive feeling. Hopefulness is more likely to foster happiness, while feelings of hopelessness tend to undermine happiness. Todd Kashdan, researcher and author of "Designing Positive Psychology", explained early science's findings should not be overgeneralized or adopted too uncritically. Mindfulness to Kashdan is very resource-intensive processing; he warned it is not simply better at all times. To illustrate, when a task is best performed with very little conscious thought (e.g., a paramedic performing practiced, emergency maneuvers). Nevertheless, development of the skill lends to its application at certain times, which can be useful for the reasons just described; Professor of Psychology and Psychiatry Richard J. Davidson highly recommends "mindfulness meditation" for use in the accurate identification and management of emotions.
Sources: en.wikipedia.org
Currently, there are 10 ACE inhibitors approved for use in the United States by the FDA: captopril (1981), enalapril (1985), lisinopril (1987), benazepril (1991), fosinopril (1991), quinapril (1991), ramipril (1991), perindopril (1993), moexipril (1995) and trandolapril (1996). ACE inhibitors are easily identifiable by their common suffix, '-pril'. ACE inhibitors can be divided into three groups based on their molecular structure of the enzyme binding sites (sulfhydryl, phosphinyl, carboxyl) to the active center of ACE: Alacepril Captopril (trade name Capoten), the first ACE inhibitor. Zofenopril These agents appear to show antioxidative properties but may be involved in adverse events such as skin eruptions. This is the largest group, including:
Uranium-236 has a half-life of about 23 million years; and is neither fissile with thermal neutrons, nor very good fertile material, but is generally considered a nuisance and long-lived radioactive waste. It is found in spent nuclear fuel and in the reprocessed uranium made from spent nuclear fuel.
==== Experimental analogues ==== Insulin tregopil is an experimental ultra-fast-acting insulin that is being developed by Biocon. Unlike other insulin analogues, it is designed to be taken orally. It has been modified with the covalent attachment of a methoxy-triethylene-glycol-propionyl moiety at Lys-β29-amino group of the B-chain. This modification, along with the use of sodium caprate as a permeation enhancer, allows insulin tregopil to be absorbed through the gastrointestinal tract. Another oral analogue called ORMD-0801 is, as of 2025, in development by Oramed Pharmaceuticals. Insulin efsitora alfa is an experimental insulin analogue developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found to be similar to insulin degludec in a phase II clinical trial. NNC2215 is a bioengineered glucose-sensitive insulin analogue developed by Novo Nordisk researchers. The drug is designed to adjust its activity based on blood glucose levels, reducing insulin sensitivity when glucose concentrations are low, thereby lowering the risk of hypoglycemia. It also provides more stable blood sugar control by responding dynamically to fluctuations in glucose levels. A study on NNC2215 was published in the journal Nature on 16 October 2024, describing its potential as a major advancement in diabetes treatment and the role of protein engineering in future medicine. The development of glucose-sensitive insulin has been an area of interest in diabetes research since 1979, aiming to address blood sugar fluctuations.
The most common liver injuries from weight loss and bodybuilding supplements involve hepatocellular damage with resulting jaundice, and the most common supplement ingredients attributed to these injuries are green tea catechins, anabolic steroids, and the herbal extract, aegeline. Weight loss supplements have also had adverse psychiatric effects. Some dietary supplements may also have adverse interactions with prescription medications that may enhance side effects or decrease therapeutic effects of medications.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.